Literature DB >> 27255940

Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery.

Tomoaki Yoh1, Etsuro Hatano2, Takahiro Nishio1, Satoru Seo1, Kojiro Taura1, Kentaro Yasuchika1, Hideaki Okajima1, Toshimi Kaido1, Shinji Uemoto1.   

Abstract

BACKGROUND: The prognosis of intrahepatic cholangiocarcinoma (ICC) remains poor despite improvements in treatment and post-operative clinical management. We review our experiences and evaluate our current surgical approaches by comparing patients from two consecutive treatment periods.
METHODS: One hundred forty-four patients who underwent hepatectomy for ICC between 1993 and 2014 were divided into groups that received treatment before (n = 65, first period) and after 2006 (n = 79, second period), when new treatment options such as adjuvant chemotherapy and multimodal therapy for recurrence were introduced. Clinicopathological characteristics and survival outcomes were compared between the groups.
RESULTS: First-period patients exhibited more advanced tumor characteristics, including larger tumors, higher serum carbohydrate antigen 19-9 levels, and vascular invasion. Median overall survival (OS) durations of the first- and second-period groups were 21.4 and 57.7 months, respectively (p < 0.001); corresponding median disease-free survival (DFS) durations were 12.2 and 16.6 months, respectively (p = 0.027). Multivariate analysis found an independent association of the treatment time period with OS and DFS. Notably, second-period patients with N1 disease achieved a longer OS and DFS (median OS time: 12.4 and 26.0 months, p = 0.0018, and median DFS: 4.7 and 10.7 months p = 0.019, respectively). Among recurrent patients (first, n = 50 and second, n = 44), second-period patients had a significantly longer survival after recurrence (8.0 vs. 22.3 months, p < 0.001).
CONCLUSION: ICC patients, particularly those with N1 disease, achieved significant survival improvements that were partly attributable to patient selection, adjuvant chemotherapy, and multimodal treatment after recurrence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27255940     DOI: 10.1007/s00268-016-3583-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival.

Authors:  Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2010-07       Impact factor: 12.969

Review 2.  Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.

Authors:  Murad Aljiffry; Alhawsawi Abdulelah; Mark Walsh; Kevork Peltekian; Ian Alwayn; Michele Molinari
Journal:  J Am Coll Surg       Date:  2008-10-31       Impact factor: 6.113

3.  Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.

Authors:  Mechteld C de Jong; Hari Nathan; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; T Clark Gamblin; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Richard D Schulick; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

4.  Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

Authors:  J W Valle; J Furuse; M Jitlal; S Beare; N Mizuno; H Wasan; J Bridgewater; T Okusaka
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

5.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

6.  Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group.

Authors:  Olivier Farges; David Fuks; Emmanuel Boleslawski; Yves-Patrice Le Treut; Denis Castaing; Alexis Laurent; Christian Ducerf; Michel Rivoire; Philippe Bachellier; Laurence Chiche; Gennaro Nuzzo; Jean Marc Regimbeau
Journal:  Ann Surg       Date:  2011-11       Impact factor: 12.969

7.  Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.

Authors:  John T Miura; Fabian M Johnston; Susan Tsai; Ben George; Jim Thomas; Dan Eastwood; Anjishnu Banerjee; Kathleen K Christians; Kiran K Turaga; Timothy M Pawlik; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

8.  Recurrence after operative management of intrahepatic cholangiocarcinoma.

Authors:  Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  Surgery       Date:  2013-03-15       Impact factor: 3.982

9.  Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients.

Authors:  Dario Ribero; Antonio Daniele Pinna; Alfredo Guglielmi; Antonio Ponti; Gennaro Nuzzo; Stefano Maria Giulini; Luca Aldrighetti; Fulvio Calise; Giorgio Enrico Gerunda; Mariano Tomatis; Marco Amisano; Pasquale Berloco; Guido Torzilli; Lorenzo Capussotti
Journal:  Arch Surg       Date:  2012-12

10.  Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Authors:  F Eckel; R M Schmid
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

View more
  9 in total

Review 1.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

2.  Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Authors:  Suguru Yamashita; Eugene Jon Koay; Guillaume Passot; Rachna Shroff; Kanwal P Raghav; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Randa Tao; Ahmed Kaseb; Milind Javle; Christopher H Crane; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

3.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

4.  Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis.

Authors:  Xian Shen; Huanhu Zhao; Xing Jin; Junyu Chen; Zhengping Yu; Kuvaneshan Ramen; Xiangwu Zheng; Xiuling Wu; Yunfeng Shan; Jianling Bai; Qiyu Zhang; Qiqiang Zeng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

5.  Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery.

Authors:  Tomoaki Yoh; Etsuro Hatano; Satoru Seo; Yukihiro Okuda; Hiroaki Fuji; Yoshinobu Ikeno; Kojiro Taura; Kentaro Yasuchika; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

Review 6.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

7.  A novel prognostic model for diagnosing atypical bile duct hyperplasia in patients with intrahepatic lithiasis.

Authors:  Hongcheng Lu; Hao Yang; Linquan Wu; Wenjun Liao; Xianping He; Enliang Li; Rongshou Wu; Shidai Shi; Zhilong Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

8.  Impact of 18F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma.

Authors:  Lena Sophie Kiefer; Julia Sekler; Brigitte Gückel; Mareen Sarah Kraus; Christian la Fougère; Konstantin Nikolaou; Michael Bitzer; Sergios Gatidis; Christina Pfannenberg
Journal:  BJR Open       Date:  2021-07-05

9.  The combination of preoperative D-dimer and CA19-9 predicts lymph node metastasis and survival in intrahepatic cholangiocarcinoma patients after curative resection.

Authors:  Qichen Chen; Yiling Zheng; Hong Zhao; Jianqiang Cai; Liming Wang; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Jianxiong Wu
Journal:  Ann Transl Med       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.